Contraceptive Drug

Contraceptive Drug Market Outlook

The global contraceptive drug market is projected to reach USD 40 billion by 2035, growing at a CAGR of approximately 6.5% from 2025 to 2035. This growth is fueled by several factors, including increasing awareness regarding family planning, a rising prevalence of sexually transmitted diseases, and the growing importance of reproductive health. Moreover, the rising number of women entering the workforce and prioritizing education and career over early family planning contributes to the increasing demand for effective contraceptive options. The expansion of healthcare infrastructure and the rising availability of contraceptive products across various distribution channels also play a significant role in driving market growth. Additionally, the ongoing innovations in contraceptive methods, including long-acting reversible contraceptives, are set to further enhance market dynamics.

Growth Factor of the Market

The growth of the contraceptive drug market is significantly influenced by changing societal attitudes toward reproductive health and family planning. Governments, NGOs, and healthcare organizations are increasingly investing in educational programs to empower women to make informed choices regarding their reproductive health. Furthermore, advancements in contraceptive technologies have led to the development of new, more effective, and safer contraceptive methods, thereby increasing user acceptance and adherence to these products. The rising incidence of unintended pregnancies, coupled with the increasing demand for effective contraceptive options, has further propelled market growth. Additionally, the proliferation of e-commerce and online pharmacies has made access to contraceptive products easier than ever, removing barriers to obtaining these vital medications. Lastly, the increasing focus on personalized healthcare solutions has opened avenues for tailored contraceptive drugs that better meet individual needs.

Key Highlights of the Market

• The global contraceptive drug market is projected to reach USD 40 billion by 2035.
• Oral contraceptives remain the most widely used form of contraception.
• Increasing awareness of reproductive health is driving market growth.
• Technological advancements are leading to safer and more effective contraceptive methods.
• Online pharmacies are significantly enhancing the accessibility of contraceptive products.

By Product Type

Oral Contraceptives:

Oral contraceptives constitute a major segment of the contraceptive drug market, primarily due to their widespread acceptance and ease of use. These products are available in various formulations, including combination pills that contain both estrogen and progestin, as well as progestin-only pills. The convenience of a daily regimen and the ability to easily discontinue use contribute to their popularity among users. Moreover, oral contraceptives are often associated with additional health benefits, such as regulation of menstrual cycles and treatment of hormonal imbalances, which further enhance their appeal. Innovations in formulation, such as extended-cycle pills, which reduce the frequency of menstruation, are also gaining traction, attracting a broader user base.

Injectable Contraceptives:

Injectable contraceptives represent another significant category within the contraceptive drug market. These products, typically administered every three months, provide a long-lasting solution for contraception without the need for daily adherence. The efficacy of injectable contraceptives is a key selling point, as they offer high levels of prevention against unintended pregnancies. Additionally, injectable contraceptives are particularly advantageous for women who may struggle with remembering daily pills or prefer a more discreet method of contraception. The availability of various formulations, including depot medroxyprogesterone acetate (DMPA), has further diversified this market segment, catering to different user preferences and medical needs.

Intrauterine Devices:

Intrauterine devices (IUDs) have gained significant recognition as a highly effective long-term contraceptive option. These small, T-shaped devices are inserted into the uterus and can provide contraception for several years, making them a cost-effective choice for many women. The appeal of IUDs is enhanced by their low maintenance and high efficacy rates, with some devices also offering non-contraceptive benefits, such as reduced menstrual bleeding. As IUDs continue to evolve with the introduction of hormonal options, which release progestin to provide added benefits, they are becoming an increasingly preferred choice among women seeking long-term solutions for family planning.

Contraceptive Implants:

Contraceptive implants are another innovative method that has gained traction in the contraceptive drug market. These small, flexible rods are inserted under the skin and release hormones to prevent ovulation for an extended period, typically up to three years. The appeal of contraceptive implants lies in their long-term effectiveness and reversibility, offering women a hassle-free option for family planning. As more healthcare providers become trained in the insertion and removal of these implants, their market penetration is expected to increase significantly. Additionally, the ability to provide contraception without the need for daily or monthly intervention aligns well with the preferences of modern women.

Contraceptive Patches:

Contraceptive patches are a relatively newer addition to the contraceptive drug market, providing a novel alternative to traditional methods. These patches are applied to the skin and release hormones to prevent ovulation, offering the convenience of a weekly application. The ease of use and discretion of patches are key factors driving their adoption, particularly among younger populations who may prefer non-invasive methods of contraception. Moreover, the patches can be worn on various parts of the body, making them a flexible option for users. The growing awareness of the range of contraceptive options available is likely to fuel market growth in this segment.

By Application

Birth Control:

The primary application of contraceptive drugs remains birth control, which is essential for managing population growth and ensuring reproductive health. As societal norms evolve, the demand for reliable birth control methods continues to increase across various demographics. This segment drives significant revenue within the contraceptive drug market, with various options available to meet diverse user needs. The emphasis on reproductive rights and family planning initiatives worldwide has further accelerated the adoption of contraceptive methods, making birth control a central theme in the market landscape.

Hormonal Imbalance:

Contraceptive drugs also play a crucial role in managing hormonal imbalances, providing solutions for women experiencing symptoms related to conditions like polycystic ovary syndrome (PCOS) and endometriosis. By regulating hormonal levels, these products help alleviate symptoms such as irregular periods, excessive hair growth, and severe menstrual pain. The growing recognition of hormonal health issues among women and the willingness to seek medical assistance for treatment have resulted in increased utilization of contraceptive drugs for this application. Moreover, the expanding availability of specialized formulations targeting hormonal imbalances is likely to drive growth within this segment.

Acne Treatment:

Interestingly, contraceptive drugs are increasingly being recognized for their role in acne treatment, particularly among women. Certain oral contraceptives are approved for the management of acne due to their ability to lower androgen levels, which can contribute to acne flare-ups. The dual benefit of treating acne while providing contraceptive protection makes these products appealing to many young women. As awareness of this connection grows, more individuals may consider contraceptive options as a part of their acne treatment regimen, thus expanding the market reach of these products.

Polycystic Ovary Syndrome:

Polycystic ovary syndrome (PCOS) is a prevalent condition affecting many women of reproductive age, and contraceptive drugs have emerged as a vital tool in its management. These medications help regulate menstrual cycles and reduce the symptoms associated with PCOS, including acne and excess hair growth. The connection between PCOS and hormonal imbalance underscores the importance of contraceptive drugs in addressing both conditions effectively. As awareness of PCOS increases and more women seek treatment options, the application of contraceptive drugs for managing this condition is expected to drive market growth.

Endometriosis:

Endometriosis is another condition for which contraceptive drugs are frequently prescribed. The hormonal treatments provided by these medications can help reduce the severity of endometriosis symptoms, including chronic pelvic pain and heavy menstrual bleeding. By offering a non-invasive solution for managing endometriosis, contraceptive drugs have become an integral part of treatment plans for many women. Increased awareness of endometriosis and the impact it can have on quality of life is likely to stimulate demand for these contraceptive options, further contributing to market expansion.

By Distribution Channel

Hospitals & Clinics:

The hospital and clinic channel represents a significant distribution avenue for contraceptive drugs, as these healthcare institutions often serve as primary points of care for reproductive health services. Healthcare professionals provide comprehensive counseling to patients regarding their contraceptive options, fostering informed decision-making. Moreover, hospitals and clinics offer a range of contraceptive products, including long-acting methods, making them a reliable source for users seeking personalized care. The patient-provider relationship established in these settings often encourages adherence to prescribed contraceptive methods, supporting patient outcomes and driving market growth in this channel.

Retail Pharmacies:

Retail pharmacies serve as a crucial distribution channel for contraceptive drugs, providing consumers with easy access to a variety of contraceptive options. The convenience of purchasing these products over the counter appeals to many users, particularly those who prefer discretion or are not seeking a medical consultation. Retail pharmacies often carry a broad range of contraceptive choices, including oral contraceptives, patches, and condoms, catering to diverse user preferences. Additionally, the increasing acceptance of contraceptive products in public spaces has contributed to the growth of this channel, as consumers become more comfortable purchasing reproductive health products.

Online Pharmacies:

The rise of online pharmacies has transformed the distribution landscape for contraceptive drugs, allowing consumers to obtain medications from the comfort of their homes. This convenience is particularly appealing to younger populations who may prefer discreet shopping experiences. Online pharmacies offer a wide array of contraceptive options, often with the added benefits of competitive pricing and home delivery. The growth of telemedicine has also facilitated consultations with healthcare providers, enabling users to receive prescriptions and follow-up care through digital platforms. As more individuals recognize the advantages of online pharmacies, this channel is expected to witness significant growth in the contraceptive drug market.

Direct Sales:

Direct sales represent an emerging channel for contraceptive drug distribution, characterized by companies selling products directly to consumers through representatives or online platforms. This approach allows for personalized marketing and education, helping to inform consumers about various contraceptive options. Direct sales can cater to niche markets and provide tailored solutions that align with specific user needs. As companies continue to explore innovative distribution methods to engage customers, direct sales channels may play a significant role in the future of the contraceptive drug market.

By Ingredient Type

Progesterone:

Progesterone is a critical ingredient in many contraceptive drugs, particularly in hormonal contraceptives like pills, injections, and implants. As a natural hormone involved in the menstrual cycle, progesterone helps regulate ovulation and maintain uterine health. Its use in contraceptives effectively prevents pregnancy by inhibiting ovulation and altering the uterine lining. The growing understanding of progesterone's role in reproductive health has led to its application in various contraceptive formulations, contributing to the expansion of this ingredient segment in the market. The increasing demand for hormone-based contraceptive solutions will likely drive further innovation around progesterone-based products.

Estrogen:

Estrogen is another essential ingredient used in many contraceptive formulations, particularly in combination oral contraceptives. By working in tandem with progesterone, estrogen helps regulate menstrual cycles and enhances the effectiveness of contraception. The introduction of low-dose estrogen options has made it possible to minimize side effects while maintaining contraceptive efficacy. As more women seek options with fewer side effects, the demand for estrogen-containing contraceptives is expected to rise. Moreover, ongoing research into different estrogen formulations may lead to new products that cater to the evolving preferences of consumers.

Levonorgestrel:

Levonorgestrel is a widely used synthetic progestin, featured in many contraceptive pills and emergency contraceptive options. Its effectiveness in preventing ovulation and altering uterine lining makes it a critical component of various contraceptive methods. The availability of levonorgestrel in over-the-counter emergency contraception has made it more accessible to consumers, driving its market growth. As awareness about emergency contraceptive options increases, the demand for levonorgestrel-based products is likely to continue to grow, further solidifying its position in the contraceptive drug market.

Ethinyl Estradiol:

Ethinyl estradiol is a major ingredient in many combination oral contraceptives, serving as the estrogen component that contributes to the effectiveness of these products. By preventing ovulation and promoting regular menstrual cycles, ethinyl estradiol plays a crucial role in contraceptive efficacy. The continued development of new formulations that include ethinyl estradiol will likely expand its market reach, as consumers increasingly seek out effective and well-tolerated contraceptive options. Additionally, the growing trend towards personalized medicine may lead to the introduction of tailored ethinyl estradiol formulations to meet individual user requirements.

Norethindrone:

Norethindrone, another commonly used synthetic progestin, is a key ingredient in various hormonal contraceptives, including pills and implants. Its effectiveness in preventing ovulation and reducing menstrual symptoms has made it a popular choice among women. Norethindrone's ability to provide multiple health benefits beyond contraception, such as management of heavy menstrual bleeding, further enhances its appeal in the market. As research continues to uncover the broader applications and benefits of norethindrone, its presence in contraceptive formulations is expected to grow, catering to the diverse needs of women seeking reproductive health solutions.

By Region

The contraceptive drug market is experiencing various growth trajectories across different regions, driven by unique socio-economic and cultural factors. In North America, the market is projected to reach approximately USD 15 billion by 2035, with a CAGR of around 5.5%, fueled by increased access to healthcare services and a strong emphasis on reproductive rights. The rising acceptance of contraceptive methods among different demographics, particularly among younger women, significantly contributes to market expansion in this region. Furthermore, the growing trend of personalized medicine and advancements in contraceptive technology are expected to enhance the attractiveness of the market, encouraging further investment and innovation.

In Europe, the contraceptive drug market is anticipated to grow steadily, reaching nearly USD 12 billion by 2035. The market's growth is supported by comprehensive healthcare policies and a strong emphasis on women's health initiatives across various countries. The increasing prevalence of conditions like PCOS and endometriosis has driven demand for hormonal contraceptive options, further propelling market growth in this region. Additionally, the expanding range of contraceptive products available, including long-acting reversible contraceptives, will continue to shape the European contraceptive landscape. Meanwhile, the Asia Pacific region is expected to see significant growth, primarily driven by rising awareness of reproductive health, with projections estimating the market to reach around USD 8 billion by 2035.

Opportunities

There are numerous opportunities in the contraceptive drug market that stakeholders can leverage for future growth. One of the most prominent opportunities lies in the development of long-acting reversible contraceptives (LARCs). As more women seek reliable and effective contraceptive options that do not require daily attention, LARCs, such as IUDs and implants, are becoming increasingly popular. Pharmaceutical companies can invest in research and development to create innovative LARC products that offer improved efficacy, fewer side effects, and increased user comfort. Additionally, expanding access to these products in underserved regions can open up new markets and drive sales growth significantly, fostering women's health and empowerment globally.

Another noteworthy opportunity exists within education and awareness campaigns regarding reproductive health and contraceptive options. By collaborating with governments and NGOs, companies can help disseminate critical information to women and communities about available contraceptive methods, benefits, and potential side effects. This approach not only enhances brand loyalty and trust among consumers but also leads to increased demand for contraceptive products. Furthermore, the incorporation of digital health technologies, such as mobile applications for tracking menstrual cycles and medication adherence, can create additional engagement and support for users. This integration of technology into contraceptive use can further enhance market penetration and foster positive user experiences.

Threats

Despite the numerous opportunities present in the contraceptive drug market, several threats could impede growth. One of the primary challenges is the increasing scrutiny and regulation of contraceptive products by governmental and health organizations. Stricter regulations regarding clinical trials, advertising, and product labeling can delay the approval of new products and strain the resources of pharmaceutical companies attempting to bring innovations to market. Additionally, the rising awareness of potential side effects associated with hormonal contraceptives may lead some consumers to hesitate in using these products. As a result, companies must remain vigilant in conducting thorough research and addressing public concerns regarding the safety of their contraceptive options.

Another significant threat to the contraceptive drug market is the emergence of alternative family planning methods, such as natural family planning and fertility awareness. As more individuals seek holistic approaches to reproductive health, traditional contraceptive methods may face competition from these alternatives. The growing popularity of these alternatives may lead to decreased demand for pharmaceutical contraceptives, particularly among younger generations who prioritize natural and organic solutions. Companies must therefore adapt to changing consumer preferences and incorporate natural or non-hormonal options in their product offerings to remain relevant in the evolving market landscape.

Competitor Outlook

• Bayer AG
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Allergan plc
• HRA Pharma
• Johnson & Johnson
• AbbVie Inc.
• United Therapeutics Corporation
• Gedeon Richter Plc
• Watson Pharmaceuticals, Inc.
• Shionogi & Co., Ltd.
• Roche Holding AG
• Exeltis USA
• Sun Pharmaceutical Industries Ltd.

The competitive landscape of the contraceptive drug market is characterized by the presence of several key players, each vying for market share through innovative products and strategic partnerships. Major pharmaceutical companies are continually investing in research and development to introduce new contraceptive options that meet the evolving needs of consumers. For instance, many companies are focusing on developing long-acting reversible contraceptives and personalized hormonal treatments that cater to individual preferences and health requirements. Furthermore, the emphasis on addressing public health challenges, such as unintended pregnancies and sexually transmitted infections, has led to collaborative efforts among healthcare providers, governments, and NGOs, fostering a more holistic approach to reproductive health.

As the market continues to evolve, companies such as Bayer AG and Merck & Co., Inc. remain at the forefront, leveraging their extensive portfolios and established reputations to maintain leadership positions. Bayer AG, for example, is recognized for its diverse range of contraceptive products, including the Yasmin and Mirena brands. Their commitment to research and development has allowed them to introduce innovative solutions that address not only family planning but also related health concerns such as PCOS and endometriosis. Similarly, Merck & Co., Inc. has a strong presence in the contraceptive market, with products like Nexplanon and NuvaRing, which continue to garner positive reception from users seeking effective and convenient contraceptive methods.

Additionally, emerging players such as HRA Pharma and Exeltis USA are gaining traction in the contraceptive drug market by focusing on niche segments and offering specialized formulations. HRA Pharma, for instance, has successfully positioned itself as a leader in the emergency contraceptive market, emphasizing the importance of accessibility and education. Exeltis USA, on the other hand, has introduced a range of products targeting hormonal imbalances and reproductive health, capturing the interest of healthcare providers and patients alike. As competition intensifies, the ability to adapt to changing consumer needs and preferences will be crucial for companies aiming to succeed in this dynamic market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Bayer AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 HRA Pharma
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Exeltis USA
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Allergan plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gedeon Richter Plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Shionogi & Co., Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Watson Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 United Therapeutics Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Contraceptive Drug Market, By Application
    • 6.1.1 Birth Control
    • 6.1.2 Hormonal Imbalance
    • 6.1.3 Acne Treatment
    • 6.1.4 Polycystic Ovary Syndrome
    • 6.1.5 Endometriosis
  • 6.2 Contraceptive Drug Market, By Product Type
    • 6.2.1 Oral Contraceptives
    • 6.2.2 Injectable Contraceptives
    • 6.2.3 Intrauterine Devices
    • 6.2.4 Contraceptive Implants
    • 6.2.5 Contraceptive Patches
  • 6.3 Contraceptive Drug Market, By Ingredient Type
    • 6.3.1 Progesterone
    • 6.3.2 Estrogen
    • 6.3.3 Levonorgestrel
    • 6.3.4 Ethinyl Estradiol
    • 6.3.5 Norethindrone
  • 6.4 Contraceptive Drug Market, By Distribution Channel
    • 6.4.1 Hospitals & Clinics
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Direct Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Contraceptive Drug Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Contraceptive Drug market is categorized based on

By Product Type

• Oral Contraceptives
• Injectable Contraceptives
• Intrauterine Devices
• Contraceptive Implants
• Contraceptive Patches

By Application

• Birth Control
• Hormonal Imbalance
• Acne Treatment
• Polycystic Ovary Syndrome
• Endometriosis

By Distribution Channel

• Hospitals & Clinics
• Retail Pharmacies
• Online Pharmacies
• Direct Sales

By Ingredient Type

• Progesterone
• Estrogen
• Levonorgestrel
• Ethinyl Estradiol
• Norethindrone

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Bayer AG
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Allergan plc
• HRA Pharma
• Johnson & Johnson
• AbbVie Inc.
• United Therapeutics Corporation
• Gedeon Richter Plc
• Watson Pharmaceuticals, Inc.
• Shionogi & Co., Ltd.
• Roche Holding AG
• Exeltis USA
• Sun Pharmaceutical Industries Ltd.